Potential Concerns About Long-Term PPI Use

Evidence Quality and Clinical Context

• The American Gastroenterological Association notes that all studies reporting specific associations between PPIs and serious adverse events have been observational and cannot establish causality, while randomized controlled trials comparing PPIs with placebo have consistently shown no higher rate of adverse events among PPI users 1, 2
• Many reported associations lack plausible mechanisms of action and are likely explained by residual confounding and analytic biases, according to the American Gastroenterological Association 3, 2

Established Adverse Effects with Higher Probability of Causality

Gastrointestinal Infections

• PPIs may increase susceptibility to gastroenteritis and other enteric infections due to reduced gastric acid barrier, as reported by the American Academy of Pediatrics and the American Gastroenterological Association 4, 5

Rebound Acid Hypersecretion

• Common after discontinuation of long-term PPI therapy, lasting 2-6 months, representing a physiological response to secondary hypergastrinemia, according to the American Gastroenterological Association 2

Associations with Weaker or Conflicting Evidence

Cancer Risk

• No causal relationship established in RCTs regarding PPI use and cancer risk, as noted by the American Gastroenterological Association 1
• Japanese population-based data suggest possible association with gastric cancer, though rates similar to PPIs versus H2-receptor antagonists, according to the American Gastroenterological Association 5

Enterochromaffin-Like Cell Hyperplasia

• Demonstrated in up to 50% of patients receiving PPIs for >2.5 years, though considered a benign histologic change, as reported by the American Academy of Pediatrics 4
• Five-year RCT comparing vonoprazan and lansoprazole found infrequent and comparable proportions developing ECL hyperplasia, according to the American Gastroenterological Association 5

Critical Management Principles

When NOT to Discontinue PPIs

• Patients with valid indications should continue long-term PPI therapy, as recommended by the American Gastroenterological Association 1

When to Consider De-prescribing

• All patients without a definitive indication for chronic PPI should be considered for trial of de-prescribing, according to the American Gastroenterological Association 1, 2
• Most patients on twice-daily dosing should be stepped down to once-daily PPI, as recommended by the American Gastroenterological Association 1, 2

Key Clinical Pitfall

• Discontinuing PPIs in patients with definite indications based on concerns about unproven risks may lead to recurrent symptoms and serious complications, including upper GI bleeding, as noted by the American Gastroenterological Association 3

Practical Approach to Safety Monitoring

• Do not discontinue PPIs solely due to concern about potential adverse events when a valid indication exists, as recommended by the American Gastroenterological Association 2

Long-Term Issues with Proton Pump Inhibitors

Micronutrient Deficiencies

• The American Gastroenterological Association notes that large RCTs have not shown significant differences in serum B12 levels at 5 years, though these studies had methodological limitations 6, 7
• Dose-dependent associations exist between continuous PPI use and iron deficiency, particularly after ≥1 year of use 6
• The FDA includes precautionary notices regarding anemia risk 7
• Reduced gastric acid impairs iron absorption, especially non-heme iron 6
• Meta-analysis shows 71% higher risk of hypomagnesemia with PPI use (adjusted OR: 1.71; 95% CI: 1.33, 2.19) 6

Bone Health and Fractures

• Meta-analysis of 24 observational studies found 20% greater risk of hip fracture with PPI use (RR: 1.20; 95% CI: 1.14, 1.28) 6
• However, large RCTs including the COMPASS trial found no differences in fracture rates between PPI and placebo groups 6, 7
• The association appears strongest in patients with pre-existing risk factors (diabetes, CKD, arthritis) and ≥2 years of use 6

Cardiovascular Risk

• Long-term PPI use has been associated with increased risk of cardiovascular disease and morbidity in some observational studies 8, 9

Critical Management Principles

• The American Gastroenterological Association recommends that patients with Barrett's esophagus, severe erosive esophagitis, eosinophilic esophagitis with PPI response, idiopathic pulmonary fibrosis, high-risk NSAID/aspirin users requiring gastroprotection, and secondary prevention of gastric/duodenal ulcers should not be considered for de-prescribing 10, 11
• All patients without definitive indication for chronic PPI should be considered for trial of de-prescribing 10, 12
• Poor compliance with gastroprotective agents increases relative risk of adverse events 4-6 times 13
• Many associations from observational studies have not been confirmed in RCTs, suggesting substantial confounding 6, 7

Long-Term Omeprazole Use: Safety Considerations and Management

Established Risks with Higher Probability of Causality

• The American Academy of Pediatrics suggests that PPIs may increase susceptibility to gastroenteritis and other enteric infections due to reduced gastric acid barrier in pediatric patients, with long-term PPI use reported for up to 11 years in small numbers of children 14
• PPIs increase the risk of community-acquired pneumonia, but not hospital-acquired pneumonia, particularly in infants who may be at increased risk of lower respiratory tract infections 14
• Enterochromaffin-Like (ECL) Cell Hyperplasia is demonstrated in up to 50% of children receiving PPIs for >2.5 years, though considered a benign histologic change 14

Critical Management Principles

• Patients with definitive indications such as eosinophilic esophagitis with PPI response or idiopathic pulmonary fibrosis should continue long-term PPI therapy, as recommended by the European Society of Gastrointestinal Endoscopy 15
• The European Society of Gastrointestinal Endoscopy also recommends that patients with high-risk conditions, such as secondary prevention of gastric/duodenal ulcers, should continue long-term PPI therapy 15

Associations with Weaker or Conflicting Evidence

• Long-term PPI use has been associated with increased cardiovascular risk in some observational studies, although these associations have not been confirmed in randomized controlled trials, according to the American Heart Association 16

Long-Term Side Effects of Proton Pump Inhibitors

Established Adverse Effects with Strong Evidence

• The American Gastroenterological Association recommends using the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated to minimize infection risk and other adverse effects 17
• Long-term PPI use is associated with several established adverse effects including increased risk of Clostridium difficile infection, hypomagnesemia, bone fractures, acute tubulointerstitial nephritis, vitamin B12 deficiency, and rebound acid hypersecretion upon discontinuation 17, 18
• Hypomagnesemia, both symptomatic and asymptomatic, has been reported in patients treated with PPIs for at least 3 months, most commonly after 1 year of therapy 17

Risks and Management of Long-Term Proton Pump Inhibitor (PPI) Use

Established Risks with Higher Probability of Causality

• The American Gastroenterological Association suggests that PPIs increase susceptibility to Clostridium difficile colitis and bacterial gastroenteritis due to reduced gastric acid barrier, though the magnitude of risk is slight, in patients taking PPIs long-term 19
• Rebound acid hypersecretion is a common physiologic phenomenon occurring after discontinuation of long-term PPI therapy, lasting 2-6 months, resulting from hypergastrinemia-induced parietal cell proliferation during PPI therapy, and patients should be warned about potential transient upper GI symptoms when stopping PPIs 20

Clinical Management Principles

• Patients with a history of upper GI bleeding, especially with ongoing anticoagulant/antiplatelet therapy, should continue long-term PPI therapy regardless of potential risks, as recommended by the American College of Gastroenterology 20
• The American College of Gastroenterology recommends that patients at high risk for upper GI bleeding, such as those with a history of upper GI bleeding or taking multiple antithrombotics, should not be considered for PPI de-prescribing 20
• Patients should be assessed for upper GI bleeding risk using an evidence-based strategy before de-prescribing, as suggested by the American Gastroenterological Association 20

Special Considerations for Older Adults and Osteoporosis

• The 2008 American Gastroenterological Association guideline found insufficient evidence to mandate bone density studies, calcium supplementation, or any routine precaution specifically because of PPI use in older adults, but it is good medical practice to screen and treat the elderly for osteoporosis irrespective of PPI use 19

Candida Overgrowth and PPI Use

Introduction to Candida Overgrowth Risk

• The World Journal of Emergency Surgery reports that the most well-established infectious complication of PPI therapy is C. difficile infection, with meta-analyses showing increased risk (OR 1.26, 95% CI 1.12-1.39) 21, 22

PPI Use and Infection Risk

• Up to 70% of PPI use may be inappropriate, and the World Journal of Emergency Surgery suggests that PPIs are overprescribed, highlighting the need for periodic reassessment of the indication for continued therapy 21, 22

Risks and Management of Long-Term Proton Pump Inhibitor Therapy

Established Risks

• The American Gastroenterological Association notes that long-term PPI therapy is associated with an increased risk of community-acquired pneumonia, with a dose-dependent association, and 67% higher odds in long-term users (OR=1.67; 95% CI: 1.04-2.67) 23
• Long-term PPI use is also associated with an increased risk of enteric infections and gastroenteritis due to reduced gastric acid barrier 23
• The American Gastroenterological Association guideline suggests that patients on long-term PPI therapy may be at risk of bone health issues, with observational studies suggesting 42% higher odds of hip fracture (OR=1.42; 95% CI: 1.33-1.53) and 20% greater risk (RR: 1.20; 95% CI: 1.14, 1.28) 23

Management Recommendations

• The American Gastroenterological Association recommends that patients who should not discontinue PPIs include those with Barrett's esophagus, severe erosive esophagitis, and history of esophageal ulcer or peptic stricture 23
• The American Gastroenterological Association suggests that all patients without definitive indication for chronic PPI should be considered for trial of de-prescribing, including those with non-erosive reflux disease and mild erosive esophagitis 23
• The 2008 American Gastroenterological Association guideline found insufficient evidence to mandate routine bone density studies, calcium supplementation, H. pylori screening, or routine monitoring of serum creatinine, magnesium, or vitamin B12 24, 25

De-prescribing Strategy

• The American Gastroenterological Association recommends a step-wise approach to de-prescribing PPIs, including stepping down from twice-daily to once-daily dosing, tapering to lowest effective dose, and considering conversion to on-demand therapy 23
• The American Gastroenterological Association suggests that primary care providers should be primarily responsible for reviewing ongoing indications for PPI use and identifying candidates for de-prescribing 23

Evidence‑Based Management of Proton‑Pump Inhibitor Therapy

1. Indications and Ongoing Review

• All patients receiving a PPI should have their indication regularly reviewed and documented, ensuring that a valid therapeutic reason exists before continuation. 26
• Patients without a definitive indication for chronic PPI use should be considered for a trial of de‑prescribing, using an evidence‑based approach. [26][27]
• Before attempting de‑prescribing, clinicians must assess each patient’s upper‑GI bleeding risk with an evidence‑based strategy; those at high risk should not be de‑prescribed. 26

2. Optimizing Dosing and De‑prescribing Strategies

• For patients on twice‑daily PPI regimens, step‑down to once‑daily dosing is recommended whenever clinically appropriate. 26
• The lowest effective dose for the shortest necessary duration should be used for all indications. 26
• When de‑prescribing, either a gradual taper or abrupt discontinuation may be employed, based on patient preference and clinical context. 26
• Patients should be warned that transient upper‑GI symptoms (e.g., dyspepsia) may occur during tapering or after abrupt cessation due to rebound acid hypersecretion. 26

3. Adverse Effects Supported by Strong Evidence

3.1 Rebound Acid Hypersecretion

• Rebound acid hypersecretion is a common physiological phenomenon after stopping long‑term PPI therapy, typically lasting 2–6 months, and may cause transient upper‑GI symptoms. 26

3.2 Vitamin B12 Deficiency

• Long‑term daily PPI use (≥ 1 year) is dose‑dependently associated with reduced vitamin B12 absorption; however, large RCTs have not demonstrated a significant difference in serum B12 levels at 5 years, likely due to methodological limitations. 28

3.3 Iron Deficiency and Anemia

• Prolonged PPI therapy (≥ 1 year) shows a dose‑dependent relationship with iron deficiency because reduced gastric acidity impairs non‑heme iron absorption; the FDA includes precautionary labeling regarding anemia risk. 28

4. Populations Where Discontinuation Is Not Recommended Solely Based on Theoretical Risks

• In patients with chronic kidney disease, PPIs should not be stopped solely due to CKD concerns when a valid indication exists. 27
• In patients with recurrent infections, PPIs should not be discontinued solely because of infection concerns when a valid indication exists. 27

5. Clinical Pitfalls and Real‑World Impact

• Discontinuing PPIs in patients with definite indications can lead to recurrence of symptoms and serious complications, including upper‑GI bleeding. 27
• Approximately 40 % of patients have attempted PPI discontinuation without physician guidance, driven by media‑generated safety concerns. 27
• Around 75 % of physicians report altering treatment plans because of PPI safety worries, and about 80 % state they would discontinue PPIs even in high‑risk upper‑GI bleeding scenarios. 27

6. Evidence Quality Overview

• All published associations between PPIs and serious adverse events (e.g., cardiovascular disease, dementia, chronic kidney disease, mortality) are derived from observational studies and cannot establish causality. [26][27]
• No randomized controlled trial has demonstrated an increased incidence of these purported serious adverse events among PPI users. 27
• Many of these observational associations lack plausible biological mechanisms and are likely explained by residual confounding and analytic bias. 27

Strength of evidence: